Nonstructured treatment interruptions among injection drug users in Baltimore, MD

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 4, 2009, Pages 360-366

  Kavasery, Ravi ^a   Galai, Noya ^a,b   Astemborski, Jacquie ^a   Lucas, Gregory M ^c   Celentano, David D ^a   Kirk, Gregory D ^a,c   Mehta, Shruti H ^a,d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF HAIFA   (Israel)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Highly active antiretroviral therapy; Injection drug users; Treatment interruptions

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALCOHOL CONSUMPTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; UNITED STATES; BLOOD; IMMUNOLOGY; MIDDLE AGED; SUBSTANCE ABUSE; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 64249167491     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318198a800     Document Type: Article

References (19)

1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-I. EuroSIDA Study Group. Lancet. 1998;352:1725-1730.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338: 853-860.
3. Vlahov D, Galai N, Safaeian M, et al. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol. 2005;161:999-1012.
4. Pai NP, Lawrence J, Reingold AL, et al. Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults. Cochrane Database Syst Rev. 2006;3:CD006148.
5. Ananworanich J, Gayet-Ageron A, Le BM, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-I: results of the Staccato randomised trial. Lancet. 2006;368:459-465.
6. - count- guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
7. Taffe P, Rickenbach M, Hirschel B, et al. Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. AIDS. 2002;16:747-755.
8. d'Arminio MA, Cozzi-Lepri A, Phillips A, et al. Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients. J Acquir Immune Defic Syndr. 2005;38:407-416.
9. Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2005;38:320-328.
10. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15:1707-1715.
11. Mehta SH, Lucas G, Astemborski J, et al. Early immunologic and virologie responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care. 2007;19:637-645.
12. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-I infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr. 1991;109:75-100.
13. Morris JD, Golub ET, Mehta SH, et al. Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. AIDS Res Ther. 2007;4:12.
14. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251-259.
15. Lucas GM, Griswold M, Gebo KA, et al. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol. 2006;163:412-420.
16. Galai N, Safaeian M, Vlahov D, et al. Longitudinal patterns of drug injection behavior in the ALIVE Study cohort, 1988-2000: description and determinants. Am J Epidemiol. 2003;158:695-704.
17. Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006; 84:188-194.
18. Kapadia F, Vlahov D, Wu Y, et al. Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women. Am J Drug Alcohol Abuse. 2008;34:161-170.
19. Kirk GD, Vlahov D. Improving survival among HIV-infected injection drug users: how should we define success? Clin Infect Dis. 2007;45: 377-380.